Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab (Yervoy) and the PD-1 inhibitor nivolumab (Opdivo), in melanoma.
Archive | Video Reports
Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma
Posted in Melanoma News, Health Professionals, Video Reports
Neoadjuvant and Frontline Studies Guide Malignant Melanoma Treatment
The development of targeted therapies and immune checkpoint inhibitors has changed the management of malignant melanoma, providing safer and more effective treatment options and improving outcomes for many patients with this malignancy.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma
Keith T. Flaherty, MD, professor of medicine, Harvard Medical School, director, Henri and Belinda Termeer Center for Targeted Therapy, director of clinical research, Massachusetts General Hospital, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Atkins on CA209-004 Trial Results in Advanced Melanoma
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab (Opdivo) plus ipilimumab (Yervoy).
Posted in Melanoma News, Health Professionals, Video Reports
